These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11688518)

  • 21. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
    Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
    Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer.
    Oruwari JU; Chung MA; Koelliker S; Steinhoff MM; Cady B
    Am J Surg; 2002 Oct; 184(4):307-9. PubMed ID: 12383889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution.
    Xiao XS; Tang HL; Xie XH; Li LS; Kong YN; Wu MQ; Yang L; Gao J; Wei WD; Xie X
    Asian Pac J Cancer Prev; 2013; 14(9):5219-23. PubMed ID: 24175804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
    Patel T; Gupta A; Shah M
    J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival of women with locally advanced breast cancer with ≥ 10 involved lymph nodes at diagnosis.
    Zeichner SB; Cavalcante L; Suciu GP; Ruiz AL; Hirzel A; Krill-Jackson E
    Asian Pac J Cancer Prev; 2014; 15(8):3435-41. PubMed ID: 24870735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases.
    Uyan M; Koca B; Yuruker S; Ozen N
    Asian Pac J Cancer Prev; 2016; 17(3):1181-5. PubMed ID: 27039745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
    Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
    Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
    Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.
    Datta NR; Rajkumar A; Basu R
    Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer.
    Khwaja SS; Ivanovich J; DeWees TA; Ochoa L; Mullen DF; Thomas M; Margenthaler JA; Cyr A; Naughton M; Sanati S; Eberlein TJ; Gillanders WE; Aft RL; Zoberi JE; Zoberi I
    Cancer Med; 2016 Feb; 5(2):230-8. PubMed ID: 26687192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy in locally advanced breast cancer.
    Iqbal J; Shafi AA; Alharthi BN
    J Coll Physicians Surg Pak; 2014 Nov; 24(11):845-8. PubMed ID: 25404445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.